Deinove (XPAR:ALDEI) Debt-to-Asset : 1.05 (As of Jun. 2022)

View and export this data going back to 2010. Start your Free Trial

What is Deinove Debt-to-Asset?

Deinove's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was €1.43 Mil. Deinove's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was €4.85 Mil. Deinove's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2022 was €6.01 Mil. Deinove's debt to asset for the quarter that ended in Jun. 2022 was 1.05.

Deinove Debt-to-Asset Historical Data

The historical data trend for Deinove's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deinove Debt-to-Asset Chart

Deinove Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.02

0.13

0.35

0.67

Deinove Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Debt-to-Asset	Get a 7-Day Free Trial															0.16	0.35	0.38	0.67	1.05

Competitive Comparison of Deinove's Debt-to-Asset

For the Biotechnology subindustry, Deinove's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deinove's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Deinove's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Deinove's Debt-to-Asset falls into.

Deinove Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Deinove's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.634	+	4.688)	/	9.377
	=	0.67

Deinove's Debt-to-Asset for the quarter that ended in Jun. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.43	+	4.852)	/	6.011
	=	1.05

Deinove (XPAR:ALDEI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Deinove Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Deinove's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Deinove (XPAR:ALDEI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Deinove SA (XPAR:ALDEI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1682 rue de la Valsiere, Cap Sigma, ZAC Euromedecine II, Grabels, FRA, 34790

Website

http://www.deinove.com

Deinove SA is a biotechnology company engaged in the development of technologies and molecules for the health, nutrition and cosmetics industries. It is developing in two areas of activity, New-generation anti-infective ANTIBIOTICS which involves the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the challenges of antibiotic resistance; and BIOACTIVES, natural active ingredients discovers, develops and produces bioactives, active ingredients of natural origin from its bacterial biodiversity bank, to invent the new generation of sustainable cosmetics and intends to quickly bring its know-how and its products to other fields, such as nutrition and health.

Deinove (XPAR:ALDEI) Headlines

No Headlines